Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Feb 23, 2021 10:16pm
240 Views
Post# 32643955

RE:RE:RE:RE:RE:next week or so u liar?

RE:RE:RE:RE:RE:next week or so u liar?toinv,,,,,,,, I think it should be clear that our management team is in over their head and that has been evident since the middle of the BoM trial. They still have little to no idea how the drug works,,,or on what,,,or under which circumstances. Post hoc  analysys has been our saving grace since we were trying to move cholesterol out of the human ciculation system,,,,,if I recal correctly,,,,,in mice were moving as much as 30% out,,,,,,but that was quickly disproved but made for a great story in the beginning before trial,,,,,,no different than what DMcC puts out at this point.
I am purely in wait mode to dump my position, or atleast what I have originally invested.
As noted I stand to lose $27000 alone when the June warrants expire worthless.
The lack of insight into getting this technology into mainstream is paramount. Molecules left unattended,,,,,no sign of partnering,,,,,,selling our soul with each financing,,,however with each financing it makes one feel that we are not the only koolaid drinkers in the markets! Just an opinion based on present share price and the inability of this inept management team to meet mostly everything they have noted to their retail shareholders.


<< Previous
Bullboard Posts
Next >>